摘要
总结了在二年内应用去甲氧柔红霉素（Ｉｄａ）联合阿糖胞苷（Ａｒａ－ｃ）为主的方案（ＩＡ）治疗复发ＡＬＬ和ＡＭＬ。等白血病患儿２１例。结果表明１４例有效（９例ＣＲ，５例ＰＲ），其中７例为ＡＭＬ。主要副作用为骨髓抑制，全血最低期为用药后的第１２～１６．５天，约于第２６～２７天恢复正常。无明显心肌毒性作用。死亡原因为骨髓抑制最明显期导致的严重感染和出血。说明（ＶＰ）ＩＡ不仅对ＡＭＬ的疗效好，对复发ＡＬＬ上也有一定疗效。但在临床应用中，要注意其骨髓抑制的副作用，并要积极采取保护隔离和抗感染等治疗措施。
This paper summarized a regimen of therapy using idarubicin(IDA)combined with arabinoside (A) for 21 patients with refractory ALL and acute myelogenous leukemia, from 1 992 to 1994.The results showed that the(VP)IA regimen was effective in 14 patients(9 cases CR,5 cases PR),among them 7 cases suffered from AML, The chief adverse side effect of IDA was severe bone marrow suppression. The occurrebce of the lowest blood count was from 12 to 16.5 days of the treatment.It took about 2 weeks for its recovery. There was no obvious myocardial toxicity, 5 of 21 cases died of severe infection,And the hemorrhagic condition occurred during the most severe bone marrow suppression stage. The result illustrated that (VP ) IA ragimen can either achieve the favorable results to patients with AML,or benefit these suffered from ALL. Attention should be paid to the advrse side effect of bone marrow suppression,Great effort should be taken for protective isolation and anti-infection measures.
出处
《北京医学》
CAS
北大核心
1996年第4期211-213,共3页
Beijing Medical Journal
